Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Strand

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Neuropathology and Applied Neurobiology|August 13, 2004
Frontotemporal lobar degeneration and ubiquitin immunohistochemistryK A Josephs, J L Holton, M N Rossor, et al.
The Biochemical Journal|January 22, 2000
Differential recognition of snake venom proteins expressing specific Arg-Gly-Asp (RGD) sequence motifs by wild-type and variant integrin alphaIIbbeta3: further evidence for distinct sites of RGD ligand recognition exhibiting negative allosteryS Rahman, G Flynn, A Aitken, et al.
Neuropathology and Applied Neurobiology|January 20, 2019
Combined fused in sarcoma-positive (FUS+) basophilic inclusion body disease and atypical tauopathy presenting with an amyotrophic lateral sclerosis/motor neurone disease (ALS/MND)-plus phenotypeS B Wharton, N S Verber, B E Wagner, et al.
Blood|February 7, 2001
Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk-1/2 activationT Nishibe, G Parry, A Ishida, et al.
Blood Cancer Journal|July 26, 2012
AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse modelH Yao, E Ashihara, J W Strovel, et al.
American Journal of Medical Genetics. Part A|April 29, 2010
Consent for genetic research in the Framingham Heart StudyDaniel Levy, Greta Lee Splansky, Nicolle K Strand, et al.
Bioscience|March 30, 2018
The Science of Firescapes: Achieving Fire-Resilient CommunitiesAlistair M S Smith, Crystal A Kolden, Travis B Paveglio, et al.
Journal of Internal Medicine|February 15, 2019
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trialG L Goll, K K Jørgensen, J Sexton, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Neuropathology and Applied Neurobiology|August 13, 2004
Frontotemporal lobar degeneration and ubiquitin immunohistochemistryK A Josephs, J L Holton, M N Rossor, et al.
The Biochemical Journal|January 22, 2000
Differential recognition of snake venom proteins expressing specific Arg-Gly-Asp (RGD) sequence motifs by wild-type and variant integrin alphaIIbbeta3: further evidence for distinct sites of RGD ligand recognition exhibiting negative allosteryS Rahman, G Flynn, A Aitken, et al.
Neuropathology and Applied Neurobiology|January 20, 2019
Combined fused in sarcoma-positive (FUS+) basophilic inclusion body disease and atypical tauopathy presenting with an amyotrophic lateral sclerosis/motor neurone disease (ALS/MND)-plus phenotypeS B Wharton, N S Verber, B E Wagner, et al.
Blood|February 7, 2001
Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk-1/2 activationT Nishibe, G Parry, A Ishida, et al.
Blood Cancer Journal|July 26, 2012
AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse modelH Yao, E Ashihara, J W Strovel, et al.
American Journal of Medical Genetics. Part A|April 29, 2010
Consent for genetic research in the Framingham Heart StudyDaniel Levy, Greta Lee Splansky, Nicolle K Strand, et al.
Bioscience|March 30, 2018
The Science of Firescapes: Achieving Fire-Resilient CommunitiesAlistair M S Smith, Crystal A Kolden, Travis B Paveglio, et al.
Journal of Internal Medicine|February 15, 2019
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trialG L Goll, K K Jørgensen, J Sexton, et al.
Pageof 7